Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ischemic Heart Disease

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 183 articles:
HTML format
Text format



Single Articles


    November 2017
  1. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
    Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
    Am Heart J. 2017;193:63-69.
    PubMed     Text format     Abstract available


  2. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    PubMed     Text format     Abstract available


  3. AKINTOYE E, Briasoulis A, Afonso L
    Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
    Am Heart J. 2017;193:95-103.
    PubMed     Text format     Abstract available


  4. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    PubMed     Text format     Abstract available


  5. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
    Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Am Heart J. 2017;193:35-45.
    PubMed     Text format     Abstract available


  6. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
    Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
    Am Heart J. 2017;193:1-7.
    PubMed     Text format     Abstract available


  7. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    PubMed     Text format     Abstract available


    October 2017
  8. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
    The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
    Am Heart J. 2017;192:98-104.
    PubMed     Text format     Abstract available


  9. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
    Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
    Am Heart J. 2017;192:13-18.
    PubMed     Text format     Abstract available


  10. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Text format     Abstract available


  11. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
    Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
    Am Heart J. 2017;192:1-12.
    PubMed     Text format     Abstract available


    September 2017
  12. WALLERT J, Held C, Madison G, Olsson EM, et al
    Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
    Am Heart J. 2017;191:12-20.
    PubMed     Text format     Abstract available


  13. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    PubMed     Text format     Abstract available


  14. FARB A, Zuckerman BD
    Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
    Am Heart J. 2017;191:62-64.
    PubMed     Text format    


  15. REN HY, Khera A, de Lemos JA, Ayers CR, et al
    Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
    Am Heart J. 2017;191:55-61.
    PubMed     Text format     Abstract available


  16. KIM Y, Soffler M, Paradise S, Jelani QU, et al
    Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
    Am Heart J. 2017;191:47-54.
    PubMed     Text format     Abstract available


  17. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    PubMed     Text format     Abstract available


    August 2017
  18. BAGAI A, Alexander KP, Berger JS, Senior R, et al
    Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis.
    Am Heart J. 2017;190:135-139.
    PubMed     Text format     Abstract available


  19. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    PubMed     Text format     Abstract available


  20. IVERS N, Schwalm JD, Witteman HO, Presseau J, et al
    Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol.
    Am Heart J. 2017;190:64-75.
    PubMed     Text format     Abstract available


  21. PALMERINI T, Serruys P, Kappetein AP, Genereux P, et al
    Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients.
    Am Heart J. 2017;190:54-63.
    PubMed     Text format     Abstract available


  22. JIANG R, Babyak MA, Brummett BH, Hauser ER, et al
    Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort.
    Am Heart J. 2017;190:40-45.
    PubMed     Text format     Abstract available


  23. PAPENDICK C, Blyth A, Seshadri A, Edmonds MJR, et al
    A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) study.
    Am Heart J. 2017;190:25-33.
    PubMed     Text format     Abstract available


  24. SARA JDS, Prasad M, Zhang M, Lennon RJ, et al
    High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease.
    Am Heart J. 2017;190:1-11.
    PubMed     Text format     Abstract available


  25. HAMM W, Rizas KD, Stulpnagel LV, Vdovin N, et al
    Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction: Design and rationale of the SMART-MI trial.
    Am Heart J. 2017;190:34-39.
    PubMed     Text format     Abstract available


    July 2017
  26. FROBERT O, Gotberg M, Angeras O, Jonasson L, et al
    Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial.
    Am Heart J. 2017;189:94-102.
    PubMed     Text format     Abstract available


  27. NAGARAJAN V, Fonarow GC, Ju C, Pencina M, et al
    Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.
    Am Heart J. 2017;189:85-93.
    PubMed     Text format     Abstract available


  28. LEWIS EF, Wang R, Punjabi N, Gottlieb DJ, et al
    Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis.
    Am Heart J. 2017;189:59-67.
    PubMed     Text format     Abstract available


  29. VEMULAPALLI S, Lippmann SJ, Krucoff M, Hernandez AF, et al
    Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients.
    Am Heart J. 2017;189:146-157.
    PubMed     Text format     Abstract available


  30. KUTYIFA V, Beck C, Brown MW, Cannom D, et al
    Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.
    Am Heart J. 2017;189:158-166.
    PubMed     Text format     Abstract available


    June 2017
  31. SELKER HP, Udelson JE, Ruthazer R, D'Agostino RB, et al
    Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials.
    Am Heart J. 2017;188:18-25.
    PubMed     Text format     Abstract available


  32. KEDHI E, Fabris E, van der Ent M, Kennedy MW, et al
    A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Am Heart J. 2017;188:11-17.
    PubMed     Text format     Abstract available


  33. BABER U, Sartori S, Aquino M, Kini A, et al
    Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
    Am Heart J. 2017;188:73-81.
    PubMed     Text format     Abstract available


  34. VEDANTHAN R, Kamano JH, Lee H, Andama B, et al
    Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study.
    Am Heart J. 2017;188:175-185.
    PubMed     Text format     Abstract available


  35. DALBY AJ, Gottlieb S, Cyr DD, Magnus Ohman E, et al
    Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
    Am Heart J. 2017;188:156-166.
    PubMed     Text format     Abstract available


  36. ABNOUSI F, Sundaram V, Yong CM, Prats J, et al
    Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    Am Heart J. 2017;188:147-155.
    PubMed     Text format     Abstract available


  37. JOHANSEN ND, Biering-Sorensen T, Jensen JS, Mogelvang R, et al
    Diastolic dysfunction revisited: A new, feasible, and unambiguous echocardiographic classification predicts major cardiovascular events.
    Am Heart J. 2017;188:136-146.
    PubMed     Text format     Abstract available


  38. MELINA G, Angeloni E, Refice S, Monti F, et al
    Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting.
    Am Heart J. 2017;188:118-126.
    PubMed     Text format     Abstract available


  39. COUTE RA, Ehrenfeld JM, Gupta DK, Terekhov MA, et al
    Electronically self-assessed functional capacity and exercise testing: A comparison of the Duke Activity Status Index and Patient-Reported Outcomes Measurement Information System tools.
    Am Heart J. 2017;188:82-86.
    PubMed     Text format     Abstract available


  40. WIDMER RJ, Allison TG, Lennon R, Lopez-Jimenez F, et al
    Digital health intervention during cardiac rehabilitation: A randomized controlled trial.
    Am Heart J. 2017;188:65-72.
    PubMed     Text format     Abstract available


  41. KIM YG, Suh JW, Sibbing D, Kastrati A, et al
    A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis.
    Am Heart J. 2017;188:53-64.
    PubMed     Text format     Abstract available


  42. MOGENSEN UM, Kober L, Kristensen SL, Jhund PS, et al
    The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Am Heart J. 2017;188:35-41.
    PubMed     Text format     Abstract available


    May 2017
  43. KAWADA T
    beta-Blocker after acute myocardial infarction.
    Am Heart J. 2017;187:e1.
    PubMed     Text format    


  44. BAGAI A, Peterson ED, McCoy LA, Effron MB, et al
    Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of
    Am Heart J. 2017;187:19-28.
    PubMed     Text format     Abstract available


  45. KONG DF, Saito S, Nakamura S, Mehran R, et al
    Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic cor
    Am Heart J. 2017;187:112-121.
    PubMed     Text format     Abstract available


  46. DEEDWANIA P, Acharya T, Kotak K, Fonarow GC, et al
    Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.
    Am Heart J. 2017;187:78-87.
    PubMed     Text format     Abstract available


  47. PAGIDIPATI NJ, Hess CN, Clare RM, Akerblom A, et al
    An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
    Am Heart J. 2017;187:53-61.
    PubMed     Text format     Abstract available


  48. HESS CN, Clare RM, Neely ML, Tricoci P, et al
    Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
    Am Heart J. 2017;187:194-203.
    PubMed     Text format     Abstract available


  49. LAVI S, Dzavik V
    Recurrent MI and stroke post-acute coronary syndrome: Which is the lesser evil?
    Am Heart J. 2017;187:191-193.
    PubMed     Text format    


  50. LEMMERT ME, Oldroyd K, Barragan P, Lesiak M, et al
    Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicent
    Am Heart J. 2017;187:104-111.
    PubMed     Text format     Abstract available


  51. SCIAHBASI A, Rigattieri S, Sarandrea A, Cera M, et al
    Determinants of operator radiation exposure during percutaneous coronary procedures.
    Am Heart J. 2017;187:10-18.
    PubMed     Text format     Abstract available


  52. MENTZ RJ, Bethel MA, Gustavson S, Thompson VP, et al
    Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Am Heart J. 2017;187:1-9.
    PubMed     Text format     Abstract available


  53. FENDER EA, Liang JJ, Sio TT, Stulak JM, et al
    Percutaneous revascularization in patients treated with thoracic radiation for cancer.
    Am Heart J. 2017;187:98-103.
    PubMed     Text format     Abstract available


  54. FINESCHI M, Verna E, Mezzapelle G, Bartolini D, et al
    Assessing MICRO-vascular resistances via IMR to predict outcome in STEMI patients with multivessel disease undergoing primary PCI (AMICRO): Rationale and design of a prospective multicenter clinical trial.
    Am Heart J. 2017;187:37-44.
    PubMed     Text format     Abstract available


  55. LANDRAY MJ, Reveal Collaborative Group
    Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitmen
    Am Heart J. 2017;187:182-190.
    PubMed     Text format     Abstract available


    April 2017
  56. SMITS PC, Assaf A, Richardt G, Omerovic E, et al
    Design and rationale of the COMPARE-ACUTE trial: Fractional flow reserve-guided primary multivessel percutaneous coronary intervention to improve guideline indexed actual standard of care for treatment of ST-elevation myocardial infarction in patients
    Am Heart J. 2017;186:21-28.
    PubMed     Text format     Abstract available


  57. QINTAR M, Spertus JA, Tang Y, Buchanan DM, et al
    Noncardiac chest pain after acute myocardial infarction: Frequency and association with health status outcomes.
    Am Heart J. 2017;186:1-11.
    PubMed     Text format     Abstract available


  58. DUCROCQ G, Schulte PJ, Budaj A, Cornel JH, et al
    Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Am Heart J. 2017;186:91-99.
    PubMed     Text format     Abstract available


  59. SHARMA A, de Souza Brito F, Sun JL, Thomas L, et al
    Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcom
    Am Heart J. 2017;186:73-82.
    PubMed     Text format     Abstract available


  60. ENGBERS EM, Timmer JR, Mouden M, Knollema S, et al
    Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients.
    Am Heart J. 2017;186:56-62.
    PubMed     Text format     Abstract available


  61. LEE SE, Lin FY, Lu Y, Chang HJ, et al
    Rationale and design of the Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to Cardiovascular Outcomes, Cost Effectiveness and Quality of Life (CONSERVE) trial.
    Am Heart J. 2017;186:48-55.
    PubMed     Text format     Abstract available


  62. HANNAN EL, Zhong Y, Jacobs AK, Ling FSK, et al
    Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics.
    Am Heart J. 2017;186:118-126.
    PubMed     Text format     Abstract available


    March 2017
  63. LOU B, Gao H, Zhou C
    Remote ischemic conditioning in ST-segment elevation myocardial infarction: Effect of coronary collateral circulation.
    Am Heart J. 2017;185:e1.
    PubMed     Text format    


  64. NAKANISHI K, Jin Z, Homma S, Elkind MS, et al
    Left ventricular mass-geometry and silent cerebrovascular disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) study.
    Am Heart J. 2017;185:85-92.
    PubMed     Text format     Abstract available


  65. BAVISHI C, Sardar P, Chatterjee S, Khan AR, et al
    Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials.
    Am Heart J. 2017;185:26-34.
    PubMed     Text format     Abstract available


  66. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    PubMed     Text format     Abstract available


  67. KHETAN A, Purushothaman R, Zullo M, Gupta R, et al
    Rationale and design of a cluster-randomized controlled trial to evaluate the effects of a community health worker-based program for cardiovascular risk factor control in India.
    Am Heart J. 2017;185:161-172.
    PubMed     Text format     Abstract available


  68. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial.
    Am Heart J. 2017;185:154-160.
    PubMed     Text format     Abstract available


  69. YUSUF S, Joseph P
    The epidemic of cardiovascular disease in South Asians: Time for action.
    Am Heart J. 2017;185:150-153.
    PubMed     Text format    


  70. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


  71. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    PubMed     Text format     Abstract available


    February 2017
  72. VARENHORST C, Johnston N
    RE: Letter to the editor, Dr Cheng et al. "Smartphone apps and secondary prevention after myocardial infarction-How can long-term usage be improved?"
    Am Heart J. 2017;184:e2.
    PubMed     Text format    


  73. CHENG K, Oswal A
    Smartphone apps and secondary prevention after myocardial infarction - How can long-term usage be improved?
    Am Heart J. 2017;184:e1.
    PubMed     Text format    


  74. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    PubMed     Text format    


  75. WELSH RC, Roe MT, Steg PG, James S, et al
    Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100].
    Am Heart J. 2017;184:156.
    PubMed     Text format    


  76. NEWMAN JD, Rockman CB, Kosiborod M, Guo Y, et al
    Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease.
    Am Heart J. 2017;184:114-120.
    PubMed     Text format     Abstract available


  77. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    PubMed     Text format     Abstract available


  78. VOORA D, Coles A, Lee KL, Hoffmann U, et al
    An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2017;184:133-140.
    PubMed     Text format     Abstract available


  79. COFFENG JK, van der Ploeg HP, Castellano JM, Fernandez-Alvira JM, et al
    A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: Design of the TANSNIP-PESA randomized controlled trial.
    Am Heart J. 2017;184:121-132.
    PubMed     Text format     Abstract available


  80. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    PubMed     Text format     Abstract available


  81. BERWANGER O, de Barros E Silva PG, Barbosa RR, Precoma DB, et al
    Atorvastatin for high-risk statin-naive patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
    Am Heart J. 2017;184:88-96.
    PubMed     Text format     Abstract available


  82. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    PubMed     Text format     Abstract available


  83. SORENSEN LL, Liang HY, Pinheiro A, Hilser A, et al
    Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.
    Am Heart J. 2017;184:47-54.
    PubMed     Text format     Abstract available


  84. SENTHONG V, Wu Y, Hazen SL, Tang WH, et al
    Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index.
    Am Heart J. 2017;184:17-25.
    PubMed     Text format     Abstract available


    January 2017
  85. SHERWOOD A, Smith PJ, Hinderliter AL, Georgiades A, et al
    Effects of exercise and stress management training on nighttime blood pressure dipping in patients with coronary heart disease: A randomized, controlled trial.
    Am Heart J. 2017;183:85-90.
    PubMed     Text format     Abstract available


  86. LU Y, Zhou S, Dreyer RP, Caulfield M, et al
    Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study.
    Am Heart J. 2017;183:74-84.
    PubMed     Text format     Abstract available


  87. ZETTLER ME, Peterson ED, McCoy LA, Effron MB, et al
    Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events a
    Am Heart J. 2017;183:62-68.
    PubMed     Text format     Abstract available


  88. BOCCARA F, Miantezila Basilua J, Mary-Krause M, Lang S, et al
    Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy.
    Am Heart J. 2017;183:91-101.
    PubMed     Text format     Abstract available


  89. VENKATESH BA, Nauffal V, Noda C, Fujii T, et al
    Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cel
    Am Heart J. 2017;183:24-34.
    PubMed     Text format     Abstract available


  90. RIMAC G, Fearon WF, De Bruyne B, Ikeno F, et al
    Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis.
    Am Heart J. 2017;183:1-9.
    PubMed     Text format     Abstract available


    December 2016
  91. AU YEUNG SL, Lin SL, Lam HS, Schooling CM, et al
    Effect of l-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: A Mendelian randomization study.
    Am Heart J. 2016;182:54-61.
    PubMed     Text format     Abstract available


  92. RODRIGUEZ F, Lin S, Maron DJ, Knowles JW, et al
    Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines.
    Am Heart J. 2016;182:97-102.
    PubMed     Text format     Abstract available


  93. BABER U, Dangas G, Cohen DJ, Gibson CM, et al
    Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
    Am Heart J. 2016;182:125-134.
    PubMed     Text format     Abstract available


  94. GRODZINSKY A, Arnold SV, Wang TY, Sharma P, et al
    Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    Am Heart J. 2016;182:111-118.
    PubMed     Text format     Abstract available


  95. HARRISON RW, Radhakrishnan V, Lam PS, Allocco DJ, et al
    Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2016;182:103-110.
    PubMed     Text format     Abstract available


  96. LEE JM, Cho DK, Hahn JY, Song YB, et al
    Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet The
    Am Heart J. 2016;182:1-8.
    PubMed     Text format     Abstract available


  97. LEE SE, Chang HJ, Rizvi A, Hadamitzky M, et al
    Rationale and design of the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry: A comprehensive exploration of plaque progression and its impact on clinical outcomes from a multicenter seri
    Am Heart J. 2016;182:72-79.
    PubMed     Text format     Abstract available


    November 2016
  98. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    PubMed     Text format     Abstract available


  99. WELSH RC, Roe MT, Steg PG, James S, et al
    A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
    Am Heart J. 2016;181:92-100.
    PubMed     Text format     Abstract available


  100. VEROUHIS D, Sorensson P, Gourine A, Henareh L, et al
    Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction.
    Am Heart J. 2016;181:66-73.
    PubMed     Text format     Abstract available


  101. PICCARO DE OLIVEIRA P, Gonzales V, Lopes RD, Schmidt MM, et al
    Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention.
    Am Heart J. 2016;181:52-59.
    PubMed     Text format     Abstract available


  102. MONDESIR FL, Brown TM, Muntner P, Durant RW, et al
    Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS).
    Am Heart J. 2016;181:43-51.
    PubMed     Text format     Abstract available


  103. RERUP SA, Bang LE, Mogensen UM, Engstrom T, et al
    The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.
    Am Heart J. 2016;181:35-42.
    PubMed     Text format     Abstract available


  104. DERY JP, Mehta SR, Fisher HN, Zhang X, et al
    Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTud
    Am Heart J. 2016;181:26-34.
    PubMed     Text format     Abstract available


  105. WILDI K, Nelles B, Twerenbold R, Rubini Gimenez M, et al
    Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction.
    Am Heart J. 2016;181:16-25.
    PubMed     Text format     Abstract available


  106. VIRANI SS, Akeroyd JM, Ramsey DJ, Chan WJ, et al
    Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act.
    Am Heart J. 2016;181:74-82.
    PubMed     Text format     Abstract available


  107. VALENTINO M, Al Danaf J, Panakos A, Ragupathi L, et al
    Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Am Heart J. 2016;181:130-136.
    PubMed     Text format     Abstract available


  108. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    PubMed     Text format     Abstract available


  109. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Text format     Abstract available


    October 2016
  110. WINDECKER S, Tijssen J, Giustino G, Guimaraes AH, et al
    Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Am Heart J. 2016;184:81-87.
    PubMed     Text format     Abstract available


  111. AGARWAL SK, Kasula S, Almomani A, Hacioglu Y, et al
    Clinical and angiographic predictors of persistently ischemic fractional flow reserve after percutaneous revascularization.
    Am Heart J. 2016;184:10-16.
    PubMed     Text format     Abstract available


  112. SHAH R, Yow E, Jones WS, Kohl LP 3rd, et al
    Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2016;184:1-9.
    PubMed     Text format     Abstract available


  113. ALLEN JE, Knight S, McCubrey RO, Bair T, et al
    beta-blocker dosage and outcomes after acute coronary syndrome.
    Am Heart J. 2016;184:26-36.
    PubMed     Text format     Abstract available


  114. MCCARTHY CP, McEvoy JW
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection-reply.
    Am Heart J. 2016;180:e7-8.
    PubMed     Text format    


  115. RUAN X, Chiravuri S, Kaye AD
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection.
    Am Heart J. 2016;180:e5-6.
    PubMed     Text format    


  116. SRA S, Tan MK, Mehta SR, Fisher HN, et al
    Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
    Am Heart J. 2016;180:82-9.
    PubMed     Text format     Abstract available


  117. LEMKES JS, Janssens GN, Straaten HM, Elbers PW, et al
    Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.
    Am Heart J. 2016;180:39-45.
    PubMed     Text format     Abstract available


  118. NGUYEN TL, Phan J, Hogan J, Hee L, et al
    Adverse diastolic remodeling after reperfused ST-elevation myocardial infarction: An important prognostic indicator.
    Am Heart J. 2016;180:117-27.
    PubMed     Text format     Abstract available


  119. SUMMERS MR, Menon V
    Insights from cardiac imaging after ST-elevation myocardial infarction: Will increased recognition of patients at risk translate into improved long-term outcomes?
    Am Heart J. 2016;180:113-6.
    PubMed     Text format    


  120. KONTOS MC, Wang TY, Chen AY, Bates ER, et al
    The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program.
    Am Heart J. 2016;180:74-81.
    PubMed     Text format     Abstract available


  121. GIBSON CM, Korjian S, Tricoci P, Daaboul Y, et al
    Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute
    Am Heart J. 2016;180:22-8.
    PubMed     Text format     Abstract available


    September 2016
  122. TROXEL AB, Asch DA, Mehta SJ, Norton L, et al
    Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.
    Am Heart J. 2016;179:166-74.
    PubMed     Text format     Abstract available


  123. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    PubMed     Text format     Abstract available


  124. TANGUTURI VK, Wasfy JH
    Hospital readmissions after percutaneous coronary intervention aredeclining, but caution ahead is needed.
    Am Heart J. 2016;179:192-4.
    PubMed     Text format    


  125. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    PubMed     Text format     Abstract available


  126. CHANG M, Ahn JM, Kim N, Lee PH, et al
    Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents.
    Am Heart J. 2016;179:157-65.
    PubMed     Text format     Abstract available


  127. BHATNAGAR A, Bolli R, Johnstone BH, Traverse JH, et al
    Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
    Am Heart J. 2016;179:142-50.
    PubMed     Text format     Abstract available


  128. HAO Y, Liu J, Liu J, Smith SC Jr, et al
    Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome.
    Am Heart J. 2016;179:107-15.
    PubMed     Text format     Abstract available


  129. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    PubMed     Text format     Abstract available


    August 2016
  130. ABATE E, Hoogslag GE, Al Amri I, Debonnaire P, et al
    Time course, predictors, and prognostic implications of significant mitral regurgitation after ST-segment elevation myocardial infarction.
    Am Heart J. 2016;178:115-25.
    PubMed     Text format     Abstract available


  131. HARRISON RW, Simon D, Miller AL, de Lemos JA, et al
    Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;178:95-101.
    PubMed     Text format     Abstract available


  132. JOHNSTON N, Bodegard J, Jerstrom S, Akesson J, et al
    Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study.
    Am Heart J. 2016;178:85-94.
    PubMed     Text format     Abstract available


  133. SUTTON NR, Li S, Thomas L, Wang TY, et al
    The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked dat
    Am Heart J. 2016;178:65-73.
    PubMed     Text format     Abstract available


  134. DECKER C, Garavalia L, Garavalia B, Gialde E, et al
    Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention.
    Am Heart J. 2016;178:190-7.
    PubMed     Text format     Abstract available


  135. ROTHBERG MB, Martinez KA
    Risky business: Personalizing the approach to percutaneous coronary intervention.
    Am Heart J. 2016;178:185-7.
    PubMed     Text format    


  136. ARMAGANIJAN LV, Alexander KP, Huang Z, Tricoci P, et al
    Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2016;178:176-84.
    PubMed     Text format     Abstract available


  137. SELKER HP, Harris WS, Rackley CE, Marsh JB, et al
    Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial.
    Am Heart J. 2016;178:168-75.
    PubMed     Text format     Abstract available


  138. RIDKER PM, Amarenco P, Brunell R, Glynn RJ, et al
    Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Eve
    Am Heart J. 2016;178:135-44.
    PubMed     Text format     Abstract available


  139. KAUL P, Ohman EM, Knight JD, Anstrom KJ, et al
    Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary
    Am Heart J. 2016;178:55-64.
    PubMed     Text format     Abstract available


  140. CAMARO C, Damen SA, Brouwer MA, Kedhi E, et al
    Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Am Heart J. 2016;178:37-44.
    PubMed     Text format     Abstract available


  141. RAO C, Du J, Li X, Li J, et al
    Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Se
    Am Heart J. 2016;178:9-18.
    PubMed     Text format     Abstract available


  142. AKERBLOM A, Clare RM, Lokhnygina Y, Wallentin L, et al
    Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
    Am Heart J. 2016;178:1-8.
    PubMed     Text format     Abstract available


    July 2016
  143. DOLL JA, Wang TY, Choudhry NK, Cannon CP, et al
    Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarct
    Am Heart J. 2016;177:33-41.
    PubMed     Text format     Abstract available


  144. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Text format     Abstract available


  145. REN S, Hure A, Peel R, D'Este C, et al
    Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE).
    Am Heart J. 2016;177:58-65.
    PubMed     Text format     Abstract available


  146. DELGADO-LISTA J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, et al
    CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat
    Am Heart J. 2016;177:42-50.
    PubMed     Text format     Abstract available


  147. CHUN S, Choi Y, Chang Y, Cho J, et al
    Sugar-sweetened carbonated beverage consumption and coronary artery calcification in asymptomatic men and women.
    Am Heart J. 2016;177:17-24.
    PubMed     Text format     Abstract available


  148. NDREPEPA G, Iijima R, Kufner S, Braun S, et al
    Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
    Am Heart J. 2016;177:9-16.
    PubMed     Text format     Abstract available


  149. SHIMADA YJ, Bansilal S, Wiviott SD, Becker RC, et al
    Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Am Heart J. 2016;177:1-8.
    PubMed     Text format     Abstract available


    June 2016
  150. GRIMFJARD P, Erlinge D, Koul S, Lagerqvist B, et al
    Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report.
    Am Heart J. 2016;176:78-82.
    PubMed     Text format     Abstract available


  151. BLUMENTHAL JA, Feger BJ, Smith PJ, Watkins LL, et al
    Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial.
    Am Heart J. 2016;176:53-62.
    PubMed     Text format     Abstract available


  152. PATTI G, Cavallari I
    Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials.
    Am Heart J. 2016;176:36-43.
    PubMed     Text format     Abstract available


  153. GONZALEZ HM, Tarraf W, Rodriguez CJ, Gallo LC, et al
    Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results.
    Am Heart J. 2016;176:134-44.
    PubMed     Text format     Abstract available


  154. JOUNI H, Askew JW, Crusan DJ, Miller TD, et al
    Temporal trends of single-photon emission computed tomography myocardial perfusion imaging in patients without prior coronary artery disease: A 22-year experience at a tertiary academic medical center.
    Am Heart J. 2016;176:127-33.
    PubMed     Text format     Abstract available


  155. VENTURA HO, Lavie CJ
    Tackling cardiovascular disease in Hispanic/Latinos: Achieving 2020 Goals.
    Am Heart J. 2016;176:125-6.
    PubMed     Text format    


  156. MCCARTHY CP, Mullins KV, Sidhu SS, Schulman SP, et al
    The on- and off-target effects of morphine in acute coronary syndrome: A narrative review.
    Am Heart J. 2016;176:114-21.
    PubMed     Text format     Abstract available


  157. PURI R, Nissen SE, Somaratne R, Cho L, et al
    Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Am Heart J. 2016;176:83-92.
    PubMed     Text format     Abstract available


  158. DE LUCA L, Capranzano P, Patti G, Parodi G, et al
    Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
    Am Heart J. 2016;176:44-52.
    PubMed     Text format     Abstract available


  159. VAN DER HEIJDEN LC, Kok MM, Danse PW, Schramm AR, et al
    Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.
    Am Heart J. 2016;176:28-35.
    PubMed     Text format     Abstract available


  160. LOPES RD, de Paola AA, Lorga Filho AM, Consolim-Colombo FM, et al
    Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study.
    Am Heart J. 2016;176:10-6.
    PubMed     Text format     Abstract available


  161. ANDERSON LL, Dai D, Miller AL, Roe MT, et al
    Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;176:1-9.
    PubMed     Text format     Abstract available


    May 2016
  162. VAN DIJK PR, Mouden M, Hermanides R
    Directions for future trials on blood glucose-lowering drugs to improve left ventricular function post-ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:e1.
    PubMed     Text format    


  163. XU H, Li W, Yang J, Wiviott SD, et al
    The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China.
    Am Heart J. 2016;175:193-201.
    PubMed     Text format     Abstract available


  164. SILVERMAN MG, Morrow DA
    Hospital triage of acute myocardial infarction: Is admission to the coronary care unit still necessary?
    Am Heart J. 2016;175:172-4.
    PubMed     Text format    


  165. PILGRIM T, Vranckx P, Valgimigli M, Stefanini GG, et al
    Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:56-65.
    PubMed     Text format     Abstract available


  166. ERLINGE D, Koul S, Eriksson P, Schersten F, et al
    Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
    Am Heart J. 2016;175:36-46.
    PubMed     Text format     Abstract available


  167. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Ross-Fernandes MB, et al
    Corrigendum to 'The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial)' [American Heart Journal 171/1 (2016) 73-81].
    Am Heart J. 2016;175:202-203.
    PubMed     Text format    


  168. VAN DIEPEN S, Lin M, Bakal JA, McAlister FA, et al
    Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?
    Am Heart J. 2016;175:184-92.
    PubMed     Text format     Abstract available


  169. PARSH J, Seth M, Briguori C, Grossman P, et al
    The optimal definition of contrast-induced acute kidney injury for prediction of inpatient mortality in patients undergoing percutaneous coronary interventions.
    Am Heart J. 2016;175:160-7.
    PubMed     Text format     Abstract available


  170. ARBEL Y, Qiu F, Bennell MC, Austin PC, et al
    Association between publication of appropriate use criteria and the temporal trends in diagnostic angiography in stable coronary artery disease: A population-based study.
    Am Heart J. 2016;175:153-9.
    PubMed     Text format     Abstract available


  171. REED BN, Fox ER, Konig M, Jackevicius CA, et al
    The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action.
    Am Heart J. 2016;175:130-41.
    PubMed     Text format     Abstract available


  172. HUISMAN J, van der Heijden LC, Kok MM, Danse PW, et al
    Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).
    Am Heart J. 2016;175:121-9.
    PubMed     Text format     Abstract available


  173. ALLEN NB, Lloyd-Jones D, Hwang SJ, Rasmussen-Torvik L, et al
    Genetic loci associated with ideal cardiovascular health: A meta-analysis of genome-wide association studies.
    Am Heart J. 2016;175:112-20.
    PubMed     Text format     Abstract available


  174. DOBSON LE, Fairbairn TA, Musa TA, Uddin A, et al
    Sex-related differences in left ventricular remodeling in severe aortic stenosis and reverse remodeling after aortic valve replacement: A cardiovascular magnetic resonance study.
    Am Heart J. 2016;175:101-11.
    PubMed     Text format     Abstract available


  175. SHAFIQ A, Arnold SV, Gosch K, Kureshi F, et al
    Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study.
    Am Heart J. 2016;175:94-100.
    PubMed     Text format     Abstract available


  176. SIDEBOTTOM AC, Sillah A, Miedema MD, Vock DM, et al
    Changes in cardiovascular risk factors after 5 years of implementation of a population-based program to reduce cardiovascular disease: The Heart of New Ulm Project.
    Am Heart J. 2016;175:66-76.
    PubMed     Text format     Abstract available


  177. SHIMADA YJ, Cannon CP, Liu Y, Wilson C, et al
    Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care
    Am Heart J. 2016;175:18-27.
    PubMed     Text format     Abstract available


  178. MATHEWS R, Fonarow GC, Li S, Peterson ED, et al
    Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines.
    Am Heart J. 2016;175:1-8.
    PubMed     Text format     Abstract available


    April 2016
  179. GARGIULO G, Costa F, Ariotti S, Biscaglia S, et al
    Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Am Heart J. 2016;174:95-102.
    PubMed     Text format     Abstract available


  180. GUIMARAES PO, Sun JL, Kragholm K, Shah SH, et al
    Association of standard clinical and laboratory variables with red blood cell distribution width.
    Am Heart J. 2016;174:22-8.
    PubMed     Text format     Abstract available


    March 2016
  181. BRIGUORI C, Visconti G, Donahue M, De Micco F, et al
    RenalGuard system in high-risk patients for contrast-induced acute kidney injury.
    Am Heart J. 2016;173:67-76.
    PubMed     Text format     Abstract available


  182. VASSALLI G, Klersy C, De Servi S, Galatius S, et al
    Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial.
    Am Heart J. 2016;173:1-7.
    PubMed     Text format     Abstract available


    February 2016
  183. PESARO AE, Granger CB, Lopes RD
    Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?
    Am Heart J. 2016;172:42-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: